The WHO Cholera Rapid Diagnostic Test (RDT) Target Product Profile outlines the key requirements for developing improved cholera RDTs. It highlights the need for fast, accurate, and easy-to-use tests for early outbreak detection in resource-limited settings. The document sets desired and acceptable ...performance criteria, including high sensitivity and specificity, rapid results (under 15 minutes), and usability by non-laboratory personnel. The tests should be affordable, stable in extreme conditions, and require minimal training. The goal is to enhance cholera surveillance and outbreak response, ensuring quick containment and improved public health outcomes.
more
This document aims to provide advice on the detection and management of ill travellers suspected of COVID-19 infection, at international airports, ports and ground crossings. It includes the following measures; 1)Detection of ill travellers; 2) Interview of ill travellers for COVID-19; 3) Reporting ...of alerts of ill travellers with suspected COVID-19 infection and 4) Isolation, initial case management and referral of ill travellers with suspected COVID-19 infection.
more
Mortality and burden of disease attributable to selected major risks
Communications and outreach to policy-makers and the wider public are essential to mobilize and sustain support for policy solutions to air pollution and bring the needed health, environment and economic benefits.
Accessed November 2, 2017 |
SPECIAL NEEDS NETWORK |
National Association Networking for the Special Needs of the Individual
In response to COVID-19, countries around the globe have implemented several public health and social measures (PHSM), including large scale measures such as movement restrictions, closure of schools and businesses, geographical area quarantine, and international travel restrictions.
PQDx 0179-012-00 WHO
PQDx Public Report
June/2017, version 4.0
For use with travelers who might have been exposed to patients with Ebola and are sick with symptoms consistent with Ebola infection and require further evaluation
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
Interim guidance 19 March 2020